Beauty Health Co SKIN.OQ SKIN.O is expected to show a fall in quarterly revenue when it reports results on March 12 for the period ending December 31 2024
The Long Beach California-based company is expected to report a 20.1% decrease in revenue to $77.39 million from $96.8 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Beauty Health Co is for a loss of 11 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 6 "hold" and 3 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Beauty Health Co is $1.88, above its last closing price of $1.30.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.12 | -0.11 | -0.09 | Beat | 19.2 |
Jun. 30 2024 | -0.03 | -0.05 | 0.00 | Beat | 102 |
Mar. 31 2024 | -0.13 | -0.14 | -0.01 | Beat | 92.7 |
Dec. 31 2023 | -0.08 | -0.08 | -0.07 | Beat | 7.4 |
Sep. 30 2023 | 0.09 | 0.09 | 0.10 | Beat | 17.6 |
Jun. 30 2023 | 0.05 | 0.06 | 0.17 | Beat | 209.1 |
Mar. 31 2023 | -0.02 | -0.02 | -0.04 | Missed | -80 |
Dec. 31 2022 | 0.04 | 0.04 | 0.05 | Beat | 32.4 |
This summary was machine generated March 10 at 20:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。